{"id":"f-peg-interferon-alpha-2a-ribavirin","safety":{"commonSideEffects":[{"rate":"50-80","effect":"Flu-like symptoms (fever, fatigue, myalgia)"},{"rate":"10-15","effect":"Hemolytic anemia"},{"rate":"5-10","effect":"Neutropenia"},{"rate":"5-10","effect":"Thrombocytopenia"},{"rate":"10-20","effect":"Depression/mood changes"},{"rate":"20-30","effect":"Headache"},{"rate":"15-25","effect":"Insomnia"},{"rate":"20-30","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL2108508","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pegylated interferon alpha-2a is a long-acting form of interferon that binds to interferon-alpha receptors on immune cells, triggering antiviral and immunomodulatory effects including upregulation of MHC molecules and activation of natural killer cells. Ribavirin is a nucleoside analog that inhibits viral RNA-dependent RNA polymerase and depletes guanosine pools, reducing hepatitis C virus replication. The combination provides synergistic antiviral activity.","oneSentence":"Pegylated interferon alpha-2a activates innate immune responses against viral infection, while ribavirin inhibits viral RNA synthesis, together targeting hepatitis C virus replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:39:30.032Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection"}]},"trialDetails":[{"nctId":"NCT01937728","phase":"PHASE4","title":"Tailored Regimens of PEGASYS® and Ribavirin for Genotype 1 Chronic Hepatitis C Patients Trial (TARGET-1)","status":"COMPLETED","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2010-03","conditions":"Hepatitis C","enrollment":542},{"nctId":"NCT00881582","phase":"PHASE4","title":"Peginterferon Alfa-2a Plus Ribavirin Combination Treatment in Chronic Hepatitis C Post-Renal Transplant Patients","status":"COMPLETED","sponsor":"King Abdulaziz Medical City","startDate":"2009-01","conditions":"Chronic Hepatitis C, Renal Transplant","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Pegasys, Robatrol"],"phase":"marketed","status":"active","brandName":"F: Peg-interferon alpha-2a & Ribavirin","genericName":"F: Peg-interferon alpha-2a & Ribavirin","companyName":"Kaohsiung Medical University Chung-Ho Memorial Hospital","companyId":"kaohsiung-medical-university-chung-ho-memorial-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pegylated interferon alpha-2a activates innate immune responses against viral infection, while ribavirin inhibits viral RNA synthesis, together targeting hepatitis C virus replication. Used for Chronic hepatitis C virus infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}